Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SteadyMed Ltd.
Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent
The latest US FDA approval decision news and highlights from the Pink Sheet’s FDA Performance Tracker
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
The latest drug development news and highlights from our US FDA Performance Tracker.
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
- Other Names / Subsidiaries
- SteadyMed Therapeutics, Inc.